Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study

Keizo Sugimachi, Yoshihiko Maehara, Kouhei Akazawa, Yukifumi Kondo, Yasuo Kunii, Masatsugu Kitamura, Hiroyuki Yamaoka, Yutaka Takahashi, Tsuyoshi Kito, Michio Katou, Hiroshi Furukawa, Shigemitsu Takashima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We studied the effects on survival time of postoperative immuno-chemotherapy, including the streptococcal preparation OK-432, in patients with gastric cancer and synchronous peritoneal dissemination. The patients were prospectively randomized and a valid statistical assessment could be made for 109. Patients randomized to group B received therapy that is widely used in Japan to treat patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4, for 1 year. Patients randomized to group A received the same drugs as were given to group B patients plus OK-432 i.p. for 7 days, beginning on postoperative day 0, and OK-432 by intradermal injection for 1 year, at 2-week intervals. There were no differences between the two groups in any known prognostic factor or in the dose of any drug administered except for OK-432. There was no difference in the toxicity rate between the groups. In this negative trial, there was no improvement in survival time with the addition of OK-432 to MMC and UFT for patients with gastric cancer and peritoneal dissemination.

Original languageEnglish
Pages (from-to)366-370
Number of pages5
JournalCancer chemotherapy and pharmacology
Volume33
Issue number5
DOIs
Publication statusPublished - Sep 1 1994

Fingerprint

Picibanil
Chemotherapy
Stomach Neoplasms
Prospective Studies
Drug Therapy
Mitomycin
Tegafur
Uracil
Pharmaceutical Preparations
Intradermal Injections
Toxicity
Survival
Japan

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination : a prospective randomized study. / Sugimachi, Keizo; Maehara, Yoshihiko; Akazawa, Kouhei; Kondo, Yukifumi; Kunii, Yasuo; Kitamura, Masatsugu; Yamaoka, Hiroyuki; Takahashi, Yutaka; Kito, Tsuyoshi; Katou, Michio; Furukawa, Hiroshi; Takashima, Shigemitsu.

In: Cancer chemotherapy and pharmacology, Vol. 33, No. 5, 01.09.1994, p. 366-370.

Research output: Contribution to journalArticle

Sugimachi, Keizo ; Maehara, Yoshihiko ; Akazawa, Kouhei ; Kondo, Yukifumi ; Kunii, Yasuo ; Kitamura, Masatsugu ; Yamaoka, Hiroyuki ; Takahashi, Yutaka ; Kito, Tsuyoshi ; Katou, Michio ; Furukawa, Hiroshi ; Takashima, Shigemitsu. / Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination : a prospective randomized study. In: Cancer chemotherapy and pharmacology. 1994 ; Vol. 33, No. 5. pp. 366-370.
@article{667d9425feb04eabadf45d7194335041,
title = "Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study",
abstract = "We studied the effects on survival time of postoperative immuno-chemotherapy, including the streptococcal preparation OK-432, in patients with gastric cancer and synchronous peritoneal dissemination. The patients were prospectively randomized and a valid statistical assessment could be made for 109. Patients randomized to group B received therapy that is widely used in Japan to treat patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4, for 1 year. Patients randomized to group A received the same drugs as were given to group B patients plus OK-432 i.p. for 7 days, beginning on postoperative day 0, and OK-432 by intradermal injection for 1 year, at 2-week intervals. There were no differences between the two groups in any known prognostic factor or in the dose of any drug administered except for OK-432. There was no difference in the toxicity rate between the groups. In this negative trial, there was no improvement in survival time with the addition of OK-432 to MMC and UFT for patients with gastric cancer and peritoneal dissemination.",
author = "Keizo Sugimachi and Yoshihiko Maehara and Kouhei Akazawa and Yukifumi Kondo and Yasuo Kunii and Masatsugu Kitamura and Hiroyuki Yamaoka and Yutaka Takahashi and Tsuyoshi Kito and Michio Katou and Hiroshi Furukawa and Shigemitsu Takashima",
year = "1994",
month = "9",
day = "1",
doi = "10.1007/BF00686264",
language = "English",
volume = "33",
pages = "366--370",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination

T2 - a prospective randomized study

AU - Sugimachi, Keizo

AU - Maehara, Yoshihiko

AU - Akazawa, Kouhei

AU - Kondo, Yukifumi

AU - Kunii, Yasuo

AU - Kitamura, Masatsugu

AU - Yamaoka, Hiroyuki

AU - Takahashi, Yutaka

AU - Kito, Tsuyoshi

AU - Katou, Michio

AU - Furukawa, Hiroshi

AU - Takashima, Shigemitsu

PY - 1994/9/1

Y1 - 1994/9/1

N2 - We studied the effects on survival time of postoperative immuno-chemotherapy, including the streptococcal preparation OK-432, in patients with gastric cancer and synchronous peritoneal dissemination. The patients were prospectively randomized and a valid statistical assessment could be made for 109. Patients randomized to group B received therapy that is widely used in Japan to treat patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4, for 1 year. Patients randomized to group A received the same drugs as were given to group B patients plus OK-432 i.p. for 7 days, beginning on postoperative day 0, and OK-432 by intradermal injection for 1 year, at 2-week intervals. There were no differences between the two groups in any known prognostic factor or in the dose of any drug administered except for OK-432. There was no difference in the toxicity rate between the groups. In this negative trial, there was no improvement in survival time with the addition of OK-432 to MMC and UFT for patients with gastric cancer and peritoneal dissemination.

AB - We studied the effects on survival time of postoperative immuno-chemotherapy, including the streptococcal preparation OK-432, in patients with gastric cancer and synchronous peritoneal dissemination. The patients were prospectively randomized and a valid statistical assessment could be made for 109. Patients randomized to group B received therapy that is widely used in Japan to treat patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4, for 1 year. Patients randomized to group A received the same drugs as were given to group B patients plus OK-432 i.p. for 7 days, beginning on postoperative day 0, and OK-432 by intradermal injection for 1 year, at 2-week intervals. There were no differences between the two groups in any known prognostic factor or in the dose of any drug administered except for OK-432. There was no difference in the toxicity rate between the groups. In this negative trial, there was no improvement in survival time with the addition of OK-432 to MMC and UFT for patients with gastric cancer and peritoneal dissemination.

UR - http://www.scopus.com/inward/record.url?scp=0028127838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028127838&partnerID=8YFLogxK

U2 - 10.1007/BF00686264

DO - 10.1007/BF00686264

M3 - Article

C2 - 8306409

AN - SCOPUS:0028127838

VL - 33

SP - 366

EP - 370

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -